Physician profile
John J Davis
NPI 1275751612
$3,132.04
in general payments reported to CMS, 2019-2025
27 companies · $50.05 in 2025
The $50.05 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $434 · 2021: $573 · 2022: $428 · 2023: $472 · 2024: $630 · 2025: $50.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $560.48 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $439.18 | 2019-2024 | Ubrelvy |
| Pfizer INC. | $417.50 | 2019-2025 | |
| Lilly USA, LLC | $244.22 | 2019-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $212.67 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $203.44 | 2019-2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.30 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $130.55 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $128.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $72.53 | 2020-2024 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $66.32 | 2023-2024 | Trintellix |
| Amarin Pharma, INC. | $63.45 | 2020-2021 | |
| Antares Pharma, INC. | $56.57 | 2024 | Xyosted |
| Supernus Pharmaceuticals, INC. | $49.88 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $45.45 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.05 | 2019-2020 | |
| Almatica Pharma LLC | $39.43 | 2024 | Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $33.54 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $29.23 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.71 | 2022 | |
| Bausch Health US, LLC | $24.96 | 2023 | Wellbutrin, Aplenzin |
| Scilex Pharmaceuticals INC. | $21.94 | 2024 | |
| Exact Sciences Corporation | $19.36 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $19.09 | 2020 | |
| Acella Pharmaceuticals, LLC | $17.32 | 2024 | NP Thyroid 60 |
| Sanofi-Aventis U.S. LLC | $14.19 | 2022 | |
| Edwards Lifesciences Corporation | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.